– Entered collaboration with Pfizer to evaluate triplet combination of STX-478 + atirmociclib + fulvestrant in frontline patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; trial ...
-- Proceeds support further mid-stage clinical development of STX-478, a potentially best-in-class mutant-selective PI3Kα program for treatment of breast cancer and other solid tumors as a monotherapy ...
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX-478 ...
BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 ...
A clinical trial is underway for STX-478, a potential new treatment for breast cancer and other tumors, with initial results expected later this year. The first patent has been dosed in a clinical ...
Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion. The Indianapolis-based ...
Researchers from Scorpion Therapeutics Inc. presented the discovery and preclinical evaluation of a novel mutant-selective, allosteric phosphoinositide 3-kinase α (PI3Kα) inhibitor, STX-478. In vitro, ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly and Company is conducting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback